Mitoxantrone is a synthetic anthracenedione antineoplastic and immunomodulatory agent. It functions as a DNA intercalating topoisomerase II inhibitor, disrupting DNA synthesis and repair. In the Indian context, it is a critical component of chemotherapy regimens for acute leukemias, aggressive lymphomas, and is a cornerstone disease-modifying therapy for secondary progressive multiple sclerosis (MS). Its use is strictly controlled due to significant and potentially life-threatening toxicities, including cumulative dose-related cardiotoxicity and profound myelosuppression.
Adult: **AML:** 12 mg/m² IV daily for 3 days (days 1-3) in combination with cytarabine. **NHL:** 10-12 mg/m² IV every 21 days as part of regimen. **MS:** 12 mg/m² IV every 3 months. Dose is often capped at a maximum single dose.
Note: **Route:** Slow IV infusion over 15-30 minutes. **Diluent:** Dilute in at least 50 mL of 0.9% Sodium Chloride Injection or 5% Dextrose Injection. **Precaution:** MUST be administered via a free-flowing IV line into a large vein. Aspirate frequently to check for blood return to avoid extravasation. Have emergency management for extravasation ready (e.g., cold compresses). Pre-medication with antiemetics is standard.
Mitoxantrone exerts its cytotoxic and immunosuppressive effects through multiple mechanisms. Its primary action is intercalation between DNA base pairs, leading to cross-linking and strand breaks. It potently inhibits the enzyme topoisomerase II, which is essential for DNA replication and repair. This interference triggers apoptosis (programmed cell death) in rapidly dividing cells, including cancer cells and activated immune cells (e.g., T-cells, B-cells, macrophages).
Pregnancy: **Category D.** Can cause fetal harm. Teratogenic and embryotoxic in animals. Contraindicated. Women of childbearing potential must use effective contraception during and for at least 6 months after therapy. Men should use contraception during and for 3-6 months after therapy.
Driving: May cause fatigue, dizziness, or blurred vision. Patients should be cautioned against driving or operating machinery, especially during periods of peak effect.
| Other Cardiotoxic Agents (e.g., Doxorubicin, Trastuzumab) | Additive risk of cardiomyopathy and CHF. Cumulative doses of all such agents must be summed. | High |
| Myelosuppressive Chemotherapy (e.g., Cyclophosphamide, Cytarabine) | Profoundly increased risk of severe neutropenia, thrombocytopenia, and anemia. Requires intensive hematological monitoring. | High |
| Live Vaccines (e.g., MMR, Varicella, Yellow Fever) | Risk of disseminated vaccine-induced infection due to immunosuppression. Contraindicated. | High |
| Hepatotoxic Drugs (e.g., Azole antifungals, High-dose Paracetamol) | Increased risk of liver injury. Monitor LFTs closely. | Moderate |
| Drugs metabolized by CYP2D6 (e.g., some Beta-blockers, SSRIs) | Mitoxantrone is a weak inhibitor; potential for increased plasma levels of these drugs. | Low |
Same composition (Mitoxantrone (2mg/ml)), different brands: